Investigational therapies for acromegaly

Bibliography

• Melmed S. Acromegaly. N Engl J Med 2006;355:2558-73
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25(1):102-52
   PubMed Web of Science ®Google Scholar
• Melmed S, Colao A, Barkan A, et al. Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94(5):1509-17
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Lombardi G, et al. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2011;32(2):247-71
   PubMed Web of Science ®Google Scholar
• Debono M, Newell-Price J. New formulations and approaches in the medical treatment of acromegaly. Curr Opin Endocrinol Diabetes Obes 2010;17(4):350-5
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Sheppard MC, Stephens JM, et al. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 2011;14(3):284-94
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Chanson P, et al. Pituitary Society; European Neuroendocrine Association. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 2008;31(9):820-38
   PubMed Web of Science ®Google Scholar
• Grasso LF, Pivonello R, Colao A. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? Curr Opin Endocrinol Diabetes Obes 2012;19(4):288-94
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open,multicenter longitudinal study. Clin Endocrinol (Oxf) 2007;67:512-19
   PubMed Web of Science ®Google Scholar
• Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87:3013-18
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-86
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Galdiero M, et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 2009;94(10):3746-56
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Rebora A, et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 2009;71(2):237-45
   PubMed Web of Science ®Google Scholar
• Attanasio R, Lanzi R, Losa M, et al. Effects of lanreotide Autogel on growth hormone, insulin-like growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008;14(7):846-55
   PubMedGoogle Scholar
• Melmed S. Medical progress: acromegaly. N Engl J Med 2006;355(24):2558-73
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007;157(5):579-87
   PubMed Web of Science ®Google Scholar
• Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009;161(2):331-8
   PubMed Web of Science ®Google Scholar
• Teichman SL, Tuvia S, Atsmon J, et al. Octreolin™ pharmacodynamics: an oral octreotide formulation to treat acromegaly suppresses growth hormone in healthy volunteers. Endocr Rev 33(03_MeetingAbstracts) 2012:OR49-4
   Google Scholar
• Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012;97(7):2362-9
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of octreolin for acromegaly. http://clinicaltrials.gov/ct2/show/NCT01412424
   Google Scholar
• Ambrilia Reports. Positive final phase III results for its octreotide formulation C2L. Market Wire FindArticlescom. 21 March 2010. Available from: http://www.fiercebiotech.com/press-releases/ambrilia-biopharma-inc-reports-positive-final-phase-iii-results-its-octreotide-formul
   Google Scholar
• Safety and biological activity of C2L-OCT-01 PR in acromegalic patients. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00642421
   Google Scholar
• Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008;286(1-2):69-74
   PubMed Web of Science ®Google Scholar
• Petersenn S, Schopohl J, Barkan A, et al. Pasireotide Acromegaly Study Group. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010;95(6):2781-9
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146(5):707-16
   PubMed Web of Science ®Google Scholar
• Murray RD, Kim K, Ren SG, et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004;89(6):3027-32
   PubMed Web of Science ®Google Scholar
• Fedele M, De Martino I, Pivonello R, et al. SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin Cancer Res 2007;13(9):2738-44
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein M, Freda P, et al. Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study [abstracts]. Endocrine 2012;29:OC1.1
   Google Scholar
• Sheppard M, Gadelha M, Bronstein MD, et al. Pasireotide LAR and Octreotide LAR maintain GH and IGF-I suppression in patients with acromegaly: extension of a 12-month randomized, double-blind, multicenter, Phase-III study. J Klin Endokrinol Stoffe 2012;5(Special Issue 3):OC31
   Google Scholar
• Fleseriu M, Sheppard M, Bronstein M, et al. Pasireotide LAR vs octreotide LAR in patients with acromegaly: double-blind, crossover, extension period to a randomized, double-blind, multicenter, phase III study [abstracts]. Endocrine 2012;29:P1404
   Google Scholar
• Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly. Available from: http://clinicaltrials.gov/show/NCT01137682
   Google Scholar
• Colao A, Grasso LF, Pivonello R, et al. Therapy of aggressive pituitary tumors. Expert Opin Pharmacother 2011;12(10):1561-70
   PubMed Web of Science ®Google Scholar
• Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 2012;76(6):769-75
   PubMed Web of Science ®Google Scholar
• Hagen C, Schroeder HD, Hansen S, et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 2009;161(4):631-7
   PubMed Web of Science ®Google Scholar
• Morin E, Berthelet F, Weisnagel J, et al. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 2012;15(1):97-100
   PubMed Web of Science ®Google Scholar
• Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006;106:1759-65
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4
   PubMed Web of Science ®Google Scholar
• Zuhur SS, Tanik C, Karaman Ö, et al. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. Endocrine 2011;40(2):222-7
   PubMed Web of Science ®Google Scholar
• Bogazzi F, Ultimieri F, Raggi F, et al. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol 2004;150(6):863-75
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, et al. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007;148(2):903-11
   PubMed Web of Science ®Google Scholar
• Bastemir M, Akin F, Yaylali GF. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly. Neuroendocrinology 2007;86(2):119-23
   PubMed Web of Science ®Google Scholar
• Bogazzi F, Rossi G, Lombardi M, et al. Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study. J Endocrinol Invest 2011;34(2):e43-51
   PubMed Web of Science ®Google Scholar
• Kim DD, Goh J, Panossian Z, et al. Pioglitazone in acromegaly - an open-label, prospective study. Clin Endocrinol (Oxf) 2012;77(4):575-8
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006;154(3):467-77
   PubMed Web of Science ®Google Scholar
• Colao A, Arnaldi G, Beck-Peccoz P, et al. Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest 2007;30(8):693-9
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer S, Droste M, et al. German pegvisomant observational study the german ACROSTUDY: past and present. Eur J Endocrinol 2009;161(Suppl):S3-S10
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012;97(5):1589-97
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007;92(12):4598-601
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Ezzat S, D'Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 2009;71(4):549-57
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 2011;164(3):325-33
   PubMed Web of Science ®Google Scholar
• Jørgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005;90(10):5627-31
   PubMed Web of Science ®Google Scholar
• Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365(9471):1644-6
   PubMed Web of Science ®Google Scholar
• Neggers SJ, de Herder WW, Feelders RA, et al. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary 2011;14(3):253-8
   PubMed Web of Science ®Google Scholar
• Higham CE, Thomas JD, Bidlingmaier M, et al. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol 2009;161(1):21-5
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 2008;93(10):3853-9
   PubMed Web of Science ®Google Scholar
• Roemmler J, Steffin B, Gutt B, et al. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth Horm IGF Res 2010;20(5):338-44
   PubMed Web of Science ®Google Scholar
• Bernabeu I, Alvarez-Escolá C, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 2012; [Epub ahead of print]
   Web of Science ®Google Scholar